DOCSLIB.ORG

Artículos Científicos

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Artículos Científicos Editor: NOEL GONZÁLEZ GOTERA Número 183 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 110415 -170415 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. ARTÍCULOS CIENTÍFICOS Publicaciones incluidas en PubMED durante el período comprendido entre el 11 y el 17 de abril de 2015. Con “vaccin*” en título: 154 artículos recuperados. Vacunas meningococo (Neisseria meningitidis) 2. Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil. Frota AC, Milagres LG, Harrison LH, Ferreira B, Menna Barreto D, Pereira GS, Cruz AC, Pereira- Manfro W, de Oliveira RH, Abreu TF, Hofer CB. Pediatr Infect Dis J. 2015 May;34(5):e113-e118. PMID: 25876102 Related citations Select item 25875985 18. Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme. Tirani M, Meregaglia M, Melegaro A. PLoS One. 2015 Apr 13;10(4):e0123383. doi: 10.1371/journal.pone.0123383. eCollection 2015. PMID: 25874805 Related citations Select item 25874777 19. Effectiveness of Meningococcal C Conjugate Vaccine in Salvador, Brazil: A Case-Control Study. 1 Cardoso CW, Ribeiro GS, Reis MG, Flannery B, Reis JN. PLoS One. 2015 Apr 13;10(4):e0123734. doi: 10.1371/journal.pone.0123734. eCollection 2015. PMID: 25874777 Related citations Select item 25874726 83. Brazilian meningococcal C conjugate vaccine: Scaling up studies. Bastos RC, de Souza IM, da Silva MN, Silva FP, Figueira ES, Leal ML, Jessouroun E, Junior JG, Medronho RA, da Silveira IA. Vaccine. 2015 Apr 9. pii: S0264-410X(15)00427-2. doi: 10.1016/j.vaccine.2015.03.097. [Epub ahead of print] PMID: 25865466 Related citations Select item 25865249 138. The diversity of meningococcal carriage across the African meningitis belt and the impact of vaccination with a group A meningococcal conjugate vaccine. African Meningococcal Carriage Consortium. J Infect Dis. 2015 Apr 9. pii: jiv211. [Epub ahead of print] PMID: 25858956 Related citations Select item 25858860 Vacunas BCG – ONCO BCG (Mycobacterium bovis) 16. Presence of mycobacterial L-forms in human blood: Challenge of BCG vaccination. Markova N, Slavchev G, Michailova L. Hum Vaccin Immunother. 2015 Apr 15:0. [Epub ahead of print] PMID: 25874947 Related citations Select item 25874857 30. Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial. Prentice S, Webb EL, Dockrell HM, Kaleebu P, Elliott AM, Cose S. Trials. 2015 Apr 11;16(1):149. [Epub ahead of print] 2 PMID: 25872925 Related citations Select item 25872647 113. A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable- syringe jet injector to conventional technique with needle and syringe. Geldenhuys HD, Mearns H, Foster J, Saxon E, Kagina B, Saganic L, Jarrahian C, Tameris MD, Dintwe OB, Van Rooyen M, Luabeya KK, Hussey G, Scriba TJ, Hatherill M, Zehrung D. Vaccine. 2015 Apr 7. pii: S0264-410X(15)00393-X. doi: 10.1016/j.vaccine.2015.03.074. [Epub ahead of print] PMID: 25862299 Free Article Related citations Select item 25862196 121. Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination. Hesseling AC, Jaspan HB, Black GF, Nene N, Walzl G. Int J Tuberc Lung Dis. 2015 Apr;19(4):454-62. doi: 10.5588/ijtld.14.0608. PMID: 25860002 Related citations Select item 25859680 Vacunas neumococo (Streptococcus pneumoniae) 25. The economic burden of childhood invasive pneumococcal diseases and pneumonia in Taiwan: Implications for a pneumococcal vaccination program. Ho YC, Lee PL, Wang YC, Chen SC, Chen KT. Hum Vaccin Immunother. 2015 Apr 15:0. [Epub ahead of print] PMID: 25874476 Related citations Select item 25874406 44. Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years and Older: An Open-Label Study. 3 Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, Schmoele-Thoma B; study group. Clin Infect Dis. 2015 Apr 13. pii: civ287. [Epub ahead of print] PMID: 25870329 Related citations Select item 25870324 72. Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial. Cordonnier C, Labopin M, Robin C, Ribaud P, Cabanne L, Chadelat C, Cesaro S, Ljungman P. Bone Marrow Transplant. 2015 Apr 13. doi: 10.1038/bmt.2015.42. [Epub ahead of print] PMID: 25867652 Related citations Select item 25867018 120. Impact of the antipneumococcal conjugate vaccine on the occurrence of infectious respiratory diseases and hospitalization rates in children. Abrão WM, Mello LM, Silva AS, Nunes AA. Rev Soc Bras Med Trop. 2015 Jan-Feb;48(1):44-9. doi: 10.1590/0037-8682-0007-2015. Epub 2015 Jan 1. PMID: 25860463 Free Article Related citations Select item 25860002 Vacunas Salmonella 31. Recombinant Salmonella-based CEACAM6 and 4-1BBL vaccine enhances T-cell immunity and inhibits the development of colorectal cancer in rats: In vivo effects of vaccine containing 4-1BBL and CEACAM6. Jin C, Liu Y, Zhu J, Xia T, Zhang B, Fei Y, Ma B, Ye J, Chen W. Oncol Rep. 2015 Apr 7. doi: 10.3892/or.2015.3901. [Epub ahead of print] PMID: 25872647 Related citations Select item 25872609 38. Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans. 4 Wahid R, Fresnay S, Levine MM, Sztein MB. Mucosal Immunol. 2015 Apr 15. doi: 10.1038/mi.2015.24. [Epub ahead of print] PMID: 25872480 Related citations Select item 25872013 45. Safety and immunogenicity of a Vi polysaccharide-Tetanus Toxoid conjugate vaccine (Typbar-TCVTM) in healthy infants, children and adults in typhoid endemic areas: a multi-center, two-cohort (open-label/double-blind, randomized, controlled), phase III study. Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM. Clin Infect Dis. 2015 Apr 13. pii: civ295. [Epub ahead of print] PMID: 25870324 Related citations Select item 25870140 88. Development of two salmonella-based oral vaccines against human respiratory syncytial virus. Azizi Jalilian F, Yusoff K, Suhaimi S, Amini R, Sekawi Z, Jahanshiri F. J Biol Regul Homeost Agents. 2015 Jan-Mar;29(1):7-18. PMID: 25864737 Related citations Select item 25864560 Vacuna tuberculosis (Mycobacterium tuberculosis) 37. Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection. Jeyanathan M, Thanthrige-Don N, Afkhami S, Lai R, Damjanovic D, Zganiacz A, Feng X, Yao XD, Rosenthal KL, Fe Medina M, Gauldie J, Ertl HC, Xing Z. Mucosal Immunol. 2015 Apr 15. doi: 10.1038/mi.2015.29. [Epub ahead of print] PMID: 25872483 Related citations Select item 25872480 49. Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings: April 9, 2014, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA. Schrager L; Aerosol Vaccines for Tuberculosis Workshop Summary Group. 5 Vaccine. 2015 Apr 10. pii: S0264-410X(15)00379-5. doi: 10.1016/j.vaccine.2015.03.060. [Epub ahead of print] PMID: 25869894 Related citations Select item 25869893 54. Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis: Conference proceedings: November 7, 2014, National Institute of Allergy and Infectious Diseases, Rockville, Maryland USA. Schrager L; Vaccine Prevention of Sustained Mycobacterium tuberculosis Infection Summary Group. Vaccine. 2015 Apr 10. pii: S0264-410X(15)00380-1. doi: 10.1016/j.vaccine.2015.03.061. [Epub ahead of print] PMID: 25869889 Related citations Select item 25869888 103. Aeras-sponsored meeting reports: Aerosol TB vaccines, whole mycobacteria cell TB vaccines, and prevention of sustained Mycobacterium tuberculosis infection. Kaufmann SH. Vaccine. 2015 Apr 8. pii: S0264-410X(15)00444-2. doi: 10.1016/j.vaccine.2015.04.001. [Epub ahead of print] No abstract available. PMID: 25863114 Related citations Select item 25862971 Vacuna tosferina (Bordetella pertussis) 87. Bordetella pertussis infection among international travellers: The need for a rigorous implementation of vaccine policies. Gómez-Junyent J, Calvo-Cano A, Muñoz J, Gascón J. Travel Med Infect Dis. 2015 Apr 2. pii: S1477-8939(15)00046-0. doi: 10.1016/j.tmaid.2015.03.011. [Epub ahead of print] No abstract available. PMID: 25864792 Related citations Select item 2586473 6 Preservantes (Tiomersal) 108. Thiomersal-containing vaccines - a review of the current state of knowledge. Gołoś A, Lutyńska A. Przegl Epidemiol. 2015;69(1):59-64. English, Polish. PMID: 25862449 Free Article Related citations Select item 25862448 Vacunas, otras 1. Progress on adenovirus-vectored universal influenza vaccines. Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, Maosheng S. Hum Vaccin Immunother. 2015 Apr 15:0. [Epub ahead of print] PMID: 25876176 Related citations Select item 25876102 2. Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil. Frota AC, Milagres LG, Harrison LH, Ferreira B, Menna Barreto D, Pereira GS, Cruz AC, Pereira-Manfro W, de Oliveira RH, Abreu TF, Hofer CB. Pediatr Infect Dis J. 2015 May;34(5):e113-e118. PMID: 25876102 Related citations Select item 25875985 3. One More Shot for the Road: A Review and Update of Vaccinations for Pediatric International Travelers. Rebaza A, Lee PJ. Pediatr Ann. 2015 Apr 1;44(4):e89-e96. doi: 10.3928/00904481-20150410-10. 7 PMID: 25875985 Related citations Select item 25875983 4. Vaccine-Preventable Outbreaks: Still with Us After All These Years. Ruderfer D, Krilov LR. Pediatr Ann. 2015 Apr 1;44(4):e76-e81.
Load more

Recommended publications
  • Maternal Vaccines - Safety in Pregnancy
    Journal Pre-proof Maternal Vaccines - Safety in pregnancy Dr Mala Arora, FRCOG (UK), FICOG, DObst (Ire), Chairperson, Vice President, Director, Consultant, Dr Rama Lakshmi, MBBS, MD PII: S1521-6934(21)00017-1 DOI: https://doi.org/10.1016/j.bpobgyn.2021.02.002 Reference: YBEOG 2112 To appear in: Best Practice & Research Clinical Obstetrics & Gynaecology Received Date: 14 August 2020 Revised Date: 18 November 2020 Accepted Date: 6 February 2021 Please cite this article as: Arora M, Lakshmi R, Maternal Vaccines - Safety in pregnancy, Best Practice & Research Clinical Obstetrics & Gynaecology, https://doi.org/10.1016/j.bpobgyn.2021.02.002. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier Ltd. Maternal Vaccines - Safety in pregnancy Dr Mala Arora FRCOG (UK),FICOG, DObst (Ire) Chairperson ICOG 2017 Vice President FOGSI 2011 Director Noble IVF Centre, sector 14, Faridabad Consultant Fortis La Femme, GK2 New Delhi India Dr Rama Lakshmi MBBS,MD Fellowship (IVF &Reproductive Medicine) Milann Fertility Centre Bengaluru India Corresponding author: Dr Mala Arora E-mail: [email protected];Journal [email protected] Pre-proof Abstract Vaccination during pregnancy is important for active immunity of the mother against serious infectious diseases, and also for passive immunity of the neonate to infectious diseases with high morbidity and mortality.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination
    International Journal of Vaccines and Vaccination New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination Abstract Research Article Vaccines are being under investigation for the possible side effects they can Volume 4 Issue 1 - 2017 cause. In order to supply new information, an electron-microscopy investigation method was applied to the study of vaccines, aimed at verifying the presence of solid contaminants by means of an Environmental Scanning Electron Microscope equipped with an X-ray microprobe. The results of this new investigation show 1 the presence of micro- and nanosized particulate matter composed of inorganic National Council of Research of Italy, Institute for the Science elements in vaccines’ samples which is not declared among the components and and Technology of Ceramics, Italy 2International Clean Water Institute, USA 3Nanodiagnostics srl, Italy of those particulate contaminants have already been verified in other matrices whose unduly presence is, for the time being, inexplicable. A considerable part and reported in literature as non biodegradable and non biocompatible. The *Corresponding author: Dr. Antonietta Gatti, National evidence collected is suggestive of some hypotheses correlated to diseases that Council of Research of Italy, c/o Nanodiagnostics are mentioned and briefly discussed. Via E. Fermi, 1/L, 41057 San Vito (MO), Italy, Tel: 059798778; Email: Keywords: Vaccine; Disease; Contamination; Protein corona; Biocompatibility; Received: November 30, 2016 | Published: January 23, process; Quality control 2017 Toxicity; Nanoparticle; Immunogenicity; Foreign body; Environment; Industrial Introduction diseases [10,11]. Neurological damages induced in patients under hemodialysis treated with water containing Aluminum are Vaccines are one of the most notable inventions meant to reported in literature [12].
    [Show full text]
  • Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease — United States, 2013
    Morbidity and Mortality Weekly Report Weekly / Vol. 64 / No. 11 March 27, 2015 Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease — United States, 2013 Anne G. Wheaton, PhD1, Timothy J. Cunningham, PhD1, Earl S. Ford, MD1, Janet B. Croft, PhD1 (Author affiliations at end of text) Chronic obstructive pulmonary disease (COPD) is a group a random-digit–dialed telephone survey (landline and cell of progressive respiratory conditions, including emphysema phone) of noninstitutionalized civilian adults aged ≥18 years and chronic bronchitis, characterized by airflow obstruction that includes various questions about respondents’ health and and symptoms such as shortness of breath, chronic cough, risk behaviors. Response rates for BRFSS are calculated using and sputum production. COPD is an important contributor standards set by the American Association of Public Opinion to mortality and disability in the United States (1,2). Healthy Research Response Rate Formula #4.† The response rate is the People 2020 has several COPD-related objectives,* including number of respondents who completed the survey as a pro- to reduce activity limitations among adults with COPD. To portion of all eligible and likely eligible persons. The median assess the state-level prevalence of COPD and the associa- survey response rate for all states, territories, and DC in 2013 tion of COPD with various activity limitations among U.S. was 46.4%, and ranged from 29.0% to 60.3%. Additional adults, CDC analyzed data from the 2013 Behavioral Risk information is presented in the BRFSS 2013 Summary Data Factor Surveillance System (BRFSS). Among U.S. adults in Quality Report.§ all 50 states, the District of Columbia (DC), and two U.S.
    [Show full text]
  • Vaccines in a Manner Not Approved by the U.S
    Immunization 101 Laurie Courtney MSN, RN Immunization Nurse Manager Massachusetts Department Of Public Health Immunization Division 1 MAIC 2021 Presenter Disclosure Information I, Laurie Courtney, have been asked to disclose any relevant financial relationships with ACCME-defined commercial entities that are either providing financial support for this program or whose products or services are mentioned during this presentation. I have no relevant financial relationships to disclose. I may discuss the use of vaccines in a manner not approved by the U.S. Food and Drug Administration, but in accordance with ACIP recommendations MAIC 2021 2 Outline • Principles of vaccination • 2021 Immunization schedules • Vaccination and the COVID-19 pandemic • Vaccine safety and adverse events reporting • COVID-19 guidance • Resources 3 MAIC 2021 Principles of vaccination 4 Community Immunity/Herd Immunity MAIC 2021 5 https://www.mlive.com/news/2014/12/how_do_vaccinations_work_the_s.html Types of Immunity • Passive Immunity . Produced by one animal or human and transferred to another . Immediate, temporary protection . Maternal antibodies . Blood products, IG, plasma . Antitoxin . Monoclonal antibodies • Active Immunity . Protection produced by a person’s own immune system . Lasts for many years, often for a lifetime . Survive infection . Vaccination https://www.vaccines.gov/basics/types 6 MAIC 2021 Types of Vaccines • Live-attenuated vaccines MMR, LAIV, Varicella, oral polio, rotavirus, BCG • Inactivated vaccines Hep A, IIV, IPV, rabies • Subunit, recombinant, polysaccharide, and conjugate vaccines PPSV23, PCV13, Hep B, MenACWY/B, Shingrix, HPV, Hib, Pertussis • Toxoid vaccines DTaP, Tdap, Td • Messenger RNA (mRNA) vaccines COVID-19 • Viral vector vaccines COVID-19 https://www.vaccines.gov/basics/types 7 MAIC 2021 Timing and Spacing of Vaccines • Refer to ACIP General Best Practice Guidelines .
    [Show full text]
  • Vaccine Technology in Human and Animal Health: Market Assessment and Intellectual Property Landscape
    APRIL 2020 VACCINE TECHNOLOGY IN HUMAN AND ANIMAL HEALTH: MARKET ASSESSMENT AND INTELLECTUAL PROPERTY LANDSCAPE Primary Author: Rachel Nash Sector Lead: Rupert Osborn IP Pragmatics Limited London | Edinburgh | Sydney www.ip-pragmatics.com 2 | P a g e TABLE OF CONTENTS Table of Contents .................................................................................................................................... 2 1. Executive Summary ......................................................................................................................... 3 2. Introduction .................................................................................................................................... 4 3. Market overview ................................................................................................................................. 5 3.1 Human Vaccine Market ................................................................................................................. 7 3.2 Animal Vaccine Market ............................................................................................................... 15 4. Key Players ........................................................................................................................................ 20 4.1 Human Vaccines .......................................................................................................................... 21 4.2 Animal Vaccines .........................................................................................................................
    [Show full text]
  • HPV Vaccines Efficacy Vs. Effectiveness
    HPV Vaccines: Efficacy Vs. Effectiveness, Next Generation Vaccines, and Controversies Laura Koutsky University of Washington Seattle, WA USA Financial Disclosure: The University of Washington receives funds from Merck to support Laura Koutsky’s HPV vaccine research HPV-Related Diseases in the US Estimated Estimated Number Number (%) Related to HPV- Related Disease of Cases HPV-6, -11, -16, or -18 Cervical cancer 11,100 7,800 (~70%) Anal cancer 4,650 3,260 (~70%) Vulvar, vaginal, and penile 6,900 2,070 (~30%) cancers Head and neck cancers 34,000 5,100 (~15%) Recurrent respiratory 1,000 900 (~90%) papillomatosis Precancerous cervical 500,000 200,000 (~40%) lesions (CIN2+) Genital warts 500,000 425,000 (~85%) *ACS 2007, Chesson HW, Persp Repro Health 2004, Saslow D, CA Cancer 2007 Prophylactic HPV Vaccines • Two vaccines based on L1 capsid (shell) protein of HPVs • Bivalent HPV16/18, HPV2 – Cervarix® GlaxoSmithKline – Regulatory approval in 50+ countries – US FDA approval likely based on expert committee approval in September of 2009 • Quadrivalent HPV6/11/16/18, HPV4 – Gardasil® Merck – Regulatory approval in 100+ countries including the US • Recommendations – Prioritize routine vaccination of females 9 to 15 years of age Phase III Randomized Clinical Trials of HPV6/11/16/18 (Merck) or HPV16/18 (GSK) L1 VLP Vaccines in Susceptible Women (~16 to 25 Yrs) Merck Vaccine GlaxoSmithKline Vaccine (NEJM 2007;357:19) Efficacy (Lancet July 7, 2009) Efficacy Vaccine Placebo (95% CI) Vaccine Placebo (96% CI) 5865 5863 8040 8080 HPV 16/18- CIN2+ 3 62 95% 5 91 95% (85-99) (86-98) 2723 2732 HPV6/11/16/18- Genital warts 3 67 96% (86-99) Merck Vaccine: HPV6/11/16/18 L1 VLP with injections 0, 2, 6 mo.
    [Show full text]
  • Vacunas-Segg-2019-2020-2
    RECOMENDACIONES DE VACUNACIÓN PARA ADULTOS Y MAYORES Y CALENDARIOS VACUNALES 2019-2020 Las vacunas protegen tu salud y la de los que te rodean RECOMENDACIONES DE VACUNACIÓN PARA ADULTOS Y MAYORES Y CALENDARIOS VACUNALES 2019-2020 Las vacunas protegen tu salud y la de los que te rodean A efectos de transparencia, le informamos que GSK ha colaborado en la financiación de la presente publicación. Su contenido refleja las opiniones, criterios, conclusiones y/o hallazgos propios de los autores, los cuales pueden no coincidir necesariamente con los de GSK. GSK recomienda siempre la utilización de sus productos de acuerdo con la ficha técnica aprobada por las autoridades sanitarias. © SOCIEDAD ESPAÑOLA DE GERIATRÍA Y GERONTOLOGÍA Príncipe de Vergara, 57-59. 28006 Madrid Tel: 914 111 707. Fax: 915 647 944 www.segg.es • [email protected] Diseño, realización y coordinación Ni el propietario del copyright, ni el coordinador editorial, ni los patrocinado- editorial: res, ni las entidades que avalan esta obra pueden ser considerados legalmente responsables de la aparición de información inexacta, errónea o difamatoria, siendo los autores los responsables de la misma. Alberto Alcocer 13, 1.º D 28036 Madrid Los autores declaran no tener conflicto de intereses. Tel.: 91 353 33 70 • Fax: 91 353 33 73 Reservados todos los derechos. Ninguna parte de esta publicación puede ser www.imc-sa.es • [email protected] reproducida, transmitida en ninguna forma o medio alguno, electrónico o me- ISBN: 978-84-7867-697-2 cánico, incluyendo las fotocopias, grabaciones o cualquier sistema de recupera- Depósito Legal: M-19904-2019 ción de almacenaje de información, sin permiso escrito del titular del copyright.
    [Show full text]
  • Vaccination in Pads
    Review Vaccination in PADs Cinzia Milito 1,* , Valentina Soccodato 1 , Giulia Collalti 1, Alison Lanciarotta 2,3, Ilaria Bertozzi 2,3, Marcello Rattazzi 2,3, Riccardo Scarpa 2,3,† and Francesco Cinetto 2,3,† 1 Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy; [email protected] (V.S.); [email protected] (G.C.) 2 Department of Medicine, University of Padua, 35122 Padua, Italy; [email protected] (A.L.); [email protected] (I.B.); [email protected] (M.R.); [email protected] (R.S.); [email protected] (F.C.) 3 Internal Medicine I, Ca’ Foncello Hospital, 10103 Treviso, Italy * Correspondence: [email protected] † These authors equally contributed. Abstract: Primary antibody deficiencies (PADs) are the most common primary immunodeficiencies (PIDs). They can be divided into the following groups, depending on their immunological features: agammaglobulinemia; common variable immunodeficiency (CVID) isotype; hyper IgM isotype; light chain or functional deficiencies with normal B cell count; specific antibody deficiency with normal Ig concentrations and normal numbers of B cells and transient hypogammaglobulinemia of infancy. The role of vaccination in PADs is recognized as therapeutic, diagnostic and prognostic and may be used in patients with residual B-cell function to provide humoral immunity to specific infective agents. According to their content and mechanisms, vaccines are grouped as live attenuated, inactivated (conjugated, polysaccharide), mRNA or replication-deficient vector vaccines. Vaccination may be unsafe or less effective when using certain vaccines and in specific types of immunodeficiency. Inactivated vaccines can be administered in PAD patients even if they could not generate a protective Citation: Milito, C.; Soccodato, V.; response; live attenuated vaccines are not recommended in major antibody deficiencies.
    [Show full text]
  • Background Paper on Vaccination Against Typhoid Fever Using New-Generation Vaccines - to Be Presented to WHO SAGE in November 2007
    Background Paper on Vaccination against Typhoid Fever using New-Generation Vaccines - to be presented to WHO SAGE in November 2007 Typhoid Immunization Working Group: Chair: Z Bhutta Members: CL Chaignat; J Clemens; M Favorov; B Ivanoff; K Klugman; S Kariuiki; M Levine; D DeRoeck; S Szu; WHO Secretariat: D Steele Abbreviated Draft Typhoid Background Paper version 7 (September 30, 2007) Table of Contents Executive Summary I. Introduction II. The Magnitude of the Problem of Typhoid Fever A. Background on the Disease, Routes of Transmission, Risk Factors and Diagnosis B. Epidemiological Patterns of Typhoid Fever and Implications for Control Programmes B.1. The global burden of typhoid fever B.2. Country-specific incidence rates and high-risk age groups from field studies B.3. Intra-country variations C. Trends in Antibiotic Resistant Typhoid and Their Implications for the Control of Typhoid Fever D. The Economic Costs of Typhoid Illness III. Typhoid Prevention and Control Measures IV. The Case for Targeted Typhoid Immunization using New-Generation Vaccines A. Composition, Safety and Immunological Properties of the Currently-Licensed New-Generation Typhoid Vaccines A.1 Vi polysaccharide A.2 Ty21a B. The Supply, Potential Demand for, and Price of Typhoid Vaccines: Current Situation and Future Trends B.1 The supply of Vi and Ty21a vaccines B.2 Production capacity, potential demand for and prices of typhoid vaccines 1 Abbreviated Draft Typhoid Background Paper version 7 (September 30, 2007) C. Population Acceptance, Feasibility of and Demand for Typhoid Vaccination in Endemic Countries C.1 Socio-behavioral study results C.2 Vaccination coverage rates of typhoid vaccines clinical studies C.3.
    [Show full text]
  • TYPHOID VACCINE 20, Avenue Appia, CH-1211 Geneva 27 Switzerland S & Health Product April 2014
    INFORMATION SHEET OBSERVED RATE OF VACCINE REACTIONS Global Vaccine Safety Essential Medicines & Health Products TYPHOID VACCINE 20, Avenue Appia, CH-1211 Geneva 27 Switzerland s & Health Product April 2014 20, avenue Appia, Ch-1211 Geneva 27 The Vaccines Several typhoid vaccines are currently available and these can be administered orally or parenterally and are safe and efficacious for preventing typhoid fever (Fraser et al, 2007, see Table 1). Adverse events are mild in nature. Oral vaccine Live attenuated vaccine: (Ty21a) (Vivotif TM, Berna Biotech, Crucell; Zerotyph caps, Boryung). This vaccine was developed in the early 1970s, requires at least three doses for optimal protection, and is supplied as gelatin capsules coated with phthalate or sachets containing lyophilised Ty21a, a mutant strain of Salmonella enterica serovar Typhi (S. Typhi). Parenteral vaccines Monovalent typhoid vaccines: Vi polysaccharide is a well-standardized antigen that is effective in a single parenteral dose, is safer than whole-cell vaccine, and may be used in children 2 years of age or older (Plotkin and Bouveret-LeCam, 1995). The following vaccines contain the Vi antigen. Capsular polysaccharide vaccines: (ViCPS) (TypherixTM, GSK; Typhim ViTM, Sanofi Pasteur; TypBar, Bharat Biotech; Shantyph, Shanta Biotech; Typho-Vi, BioMed; Zerotyph inj, Boryung, South Korea; Typhevac-inj, Shanghai Institute of Biological Products) is a one-dose injectable solution consisting 25 µg Vi antigen prepared from the surface polysaccharide of S. Typhi strain Ty2. Conjugate vaccine: (Vi-TT), where the Vi antigen is coupled to a carrier protein. At the time of review there is only one licensed conjugate vaccine (Peda-typhTM, BioMed). It consists of Vi coupled to tetanus toxoid (TT).
    [Show full text]
  • Advisory Committee on Immunization Practices (Acip)
    – General Best Practice Guidelines for Immunization BEST PRACTICES GUIDANCE OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) Kroger A, Bahta L, Hunter P General Best Practice Guidelines for Immunization: Introduction Suggested citation: Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). [www.cdc.gov/vaccines/hcp/acip-recs/general- recs/downloads/general- recs.pdf]. Accessed on [DATE]. 1 General Best Practice Guidelines for Immunization Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) Kroger A, Bahta L, Hunter P 1. Introduction The Centers for Disease Control and Prevention (CDC) recommends routine vaccination to prevent 17 vaccine-preventable diseases that occur in infants, children, adolescents, or adults. This report provides information for clinicians and other health care providers about concerns that commonly arise when vaccinating persons of various ages. Providers and patients must navigate numerous issues, such as the timing of each dose, screening for contraindications and precautions, the number of vaccines to be administered, the educational needs of patients and parents, and interpreting and responding to adverse events. Vaccination providers help patients understand the substantial body of (occasionally conflicting) information about vaccination. This vaccination best practice guidance is intended for clinicians and other health care providers who vaccinate patients in varied settings, including hospitals, provider offices, pharmacies, schools, community health centers, and public health clinics. The updated guidelines include 1) new information on simultaneous vaccination and febrile seizures; 2) enhancement of the definition of a “precaution” to include any condition that might confuse diagnostic accuracy; 3) confirmation that if a patient is not acutely moderately or General Best Practice Guidelines for Immunization: Introduction Suggested citation: Kroger A, Bahta L, Hunter P.
    [Show full text]